Helsinn Healthcare S.A. v. Accord Healthcare, Inc. et al.
resolved- Docket:
- 1:13-cv-02101
- Filed:
- 2013-12-27
D. Del. action listed among cases asserting the '725 patent; record notes asserted sibling patents '218/'219. Resolved.
8598218
3 known cases. View patent page →
- Cases
- 3
- Active
- 0
- 3 closed
- Filed
- 2013–2015
- Top venue
- D. Delaware
- 1 case
Filing activity
Untitled case
dismissed- Filed:
- 2014-12-01
- Terminated:
- 2016-05-09
FDA Other Review document records a Hatch-Waxman suit asserting U.S. 8,518,981 and U.S. 8,598,218, referenced against NDA 207963 (Exela Pharma Sciences). The lawsuit was dismissed on May 9, 2016.
Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC
voluntarily dismissed without prejudice- Docket:
- 1:15-cv-00918
- Filed:
- 2015-10-13
- Terminated:
- 2015-12-01
Helsinn and Roche asserted U.S. Patents 7,947,724; 8,518,981; 8,598,218; 9,066,980; and 9,125,905 against Fresenius Kabi in D. Del. based on Fresenius's Notice Letter regarding NDA No. 208109 for palonosetron HCl IV. Helsinn voluntarily dismissed the action without prejudice on 2015-12-01, and it was essentially refiled in New Jersey.